OrganiGram Holdings Inc. Earnings Recaps
Q3 2026
Aug 13, 2026
Organigram’s shares surged 22.9% following its Q3 report, driven by strong contributions from the recently acquired Sanity Group and signs of recovering market share in key Canadian product segments, suggesting the market is increasingly confident in its growth and margin trajectory.
Key takeaways
- The Sanity acquisition contributed approximately EUR 24.5 million (CAD 40 million) in net revenue since consolidation, representing about 35% of consolidated revenues this quarter versus 10% previously.
- Canadian recreational cannabis market share remained steady at 11.1%, with flower category share notably rising 2 percentage points year-over-year to 12.5%.
- Improvements in vapes and infused pre-rolls helped reverse prior declines; all-in-one vape share increased 1.1 points month-over-month in June.
- Beverage and concentrate segments continued strong growth, gaining 3.1 and 3.3 percentage points in category share year-over-year respectively.
- Edibles faced sequential pressure from lower-priced competitors, prompting a planned rollout of a new ingestible innovation platform beginning in September.
Q3 2025
Aug 13, 2025
Organigram reported a record-breaking Q3 fiscal 2025, showcasing strong performance with continued leadership in Canada's cannabis market and significant international expansion efforts.
Key takeaways
- Achieved gross and net revenue records, maintaining a 11.6% market share as the top licensed producer in Canada.
- Gained momentum post-ERP integration disruption, raising overall market share to 12% by the end of July.
- Strong performance in the edibles category, reaching an 18.2% market share and successful product launches like SHRED Mac 10 party packs.
- Increased presence in the cannabis beverage market with a 6.2% share, supported by favorable regulatory conditions in various provinces.
- Continued focus on innovative product development and improved inventory management to enhance market share across categories.